TY - JOUR
T1 - Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies
T2 - A Scientific Statement from the American Heart Association
AU - Bozkurt, Biykem
AU - Colvin, Monica
AU - Cook, Jennifer
AU - Cooper, Leslie T.
AU - Deswal, Anita
AU - Fonarow, Gregg C.
AU - Francis, Gary S.
AU - Lenihan, Daniel
AU - Lewis, Eldrin F.
AU - McNamara, Dennis M.
AU - Pahl, Elfriede
AU - Vasan, Ramachandran S.
AU - Ramasubbu, Kumudha
AU - Rasmusson, Kismet
AU - Towbin, Jeffrey A.
AU - Yancy, Clyde
N1 - Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/12/6
Y1 - 2016/12/6
N2 - DCM is an important cause of HF. Characterized by the common phenotype of ventricular dilation and depressed myocardial performance, its pathogenesis varies significantly, ranging from metabolic, endocrine,autoimmune, rheumatologic, infiltrative, genetic, and infectious causes to cardiotoxins. The rapidly expanding field of molecular genetics and diagnostic and biomarker strategies will likely allow us to capture an even better understanding of how cardiomyopathies develop.Demographics and treatment also vary significantly according to the cause. Treatment should be individualized and should target the underlying cause, in addition to the standard systolic HF therapies. In certain cases,with elimination of the cause and the appropriate treatment,reversal of myocardial remodeling and recovery of cardiac dysfunction can occur. Although current clinical research strategies usually target systolic HF as a group, future studies targeting specific cardiomyopathies will be critical for detection and treatment of specific cardiomyopathies.
AB - DCM is an important cause of HF. Characterized by the common phenotype of ventricular dilation and depressed myocardial performance, its pathogenesis varies significantly, ranging from metabolic, endocrine,autoimmune, rheumatologic, infiltrative, genetic, and infectious causes to cardiotoxins. The rapidly expanding field of molecular genetics and diagnostic and biomarker strategies will likely allow us to capture an even better understanding of how cardiomyopathies develop.Demographics and treatment also vary significantly according to the cause. Treatment should be individualized and should target the underlying cause, in addition to the standard systolic HF therapies. In certain cases,with elimination of the cause and the appropriate treatment,reversal of myocardial remodeling and recovery of cardiac dysfunction can occur. Although current clinical research strategies usually target systolic HF as a group, future studies targeting specific cardiomyopathies will be critical for detection and treatment of specific cardiomyopathies.
KW - AHA Scientific Statements
KW - cardiomyopathy
KW - dilated cardiomyopathy
KW - heart failure
UR - http://www.scopus.com/inward/record.url?scp=85002761027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002761027&partnerID=8YFLogxK
U2 - 10.1161/CIR.0000000000000455
DO - 10.1161/CIR.0000000000000455
M3 - Review article
C2 - 27832612
AN - SCOPUS:85002761027
SN - 0009-7322
VL - 134
SP - e579-e646
JO - Circulation
JF - Circulation
IS - 23
ER -